CORDIS · 319661 · FP7
COMBATCANCER Combination therapies for personalized cancer medicine.
Coordinator: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL)
All cancers arise due to alterations in their genomes. Although insight into the genetic lesions in tumours by genome sequencing does already assist in selecting some drug regimens, it rarely results in disease eradication due to the emergence of drug-resistant clones. More sophisticated combination therapies in which several oncogenic pathways are targeted simultaneously or in a particular sequence are believed to hold more promise. However, at present we are unable to extract and interpret the necessary information from tumours to predict which drug regimen will be most adequate. The geneti…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €14.6M awarded to the consortium. The project runs over approximately 6 years from 2013-05-01 to 2019-04-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from NL
see all →- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · H2020 · €92.5M
- GN5-2 — GN5-2101194278 · HORIZON · €80.0M
- GN4-3 — Horizon 2020: H2020-SGA-INFRA-GEANT-2018 (Topic [a] Research and Education Networking)856726 · H2020 · €77.5M
- GN4-2 — GN4-2 Research and Education Networking - GÉANT731122 · H2020 · €59.0M
- GN5-1 — GN5-1101100680 · HORIZON · €55.0M
- BIGPICTURE — Central Repository for Digital Pathology945358 · H2020 · €32.3M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the ERC-SyG funding scheme.
- What is the EU contribution?
- The European Commission contributes €14.6M toward a total project budget of €14.6M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL).
- What is the project timeline?
- The project runs from 2013-05-01 to 2019-04-30 — approximately 6 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 319661.